Clinical trials: Graft Patency
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD).
- Trial name
- NCT04910152
- Testing
- BRD4 Inhibitor PLX51107
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hannah Choe, MD